Scarica l'app Stockscreener
2.69
0.37%
0.010
Dopo l'orario di chiusura:
2.69
Precedente Chiudi:
$2.68
Aprire:
$2.65
Volume 24 ore:
152.08K
Relative Volume:
0.66
Capitalizzazione di mercato:
$120.29M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-2.8316
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
-6.92%
1M Prestazione:
+14.47%
6M Prestazione:
-20.18%
1 anno Prestazione:
-29.21%
Intervallo 1D:
$2.63
$2.75
Intervallo di 1 settimana:
$2.56
$3.025
Portata 52W:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.69 | 119.85M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Lake Street | Buy |
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Mostra tutto
Genelux Corp Borsa (GNLX) Ultime notizie
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock - MarketBeat
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GNLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Genelux Corporation outperform in the next rallyJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Genelux Corporation to Participate in Upcoming Conferences - Yahoo Finance
Will Genelux Corporation stock continue dividend increasesMarket Activity Report & Safe Capital Growth Tips - mfd.ru
Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail
US Stocks Recap: Is Outlook Therapeutics Inc stock good for income investorsM&A Rumor & Safe Capital Growth Plans - baoquankhu1.vn
Genelux appoints Jason Litten as CMO - MSN
Brokers Offer Predictions for Genelux Q1 Earnings - Defense World
Aug Sectors: Will Genelux Corporation benefit from AI trendsExit Point & High Yield Stock Recommendations - baoquankhu1.vn
Aug Momentum: Will Genelux Corporation benefit from AI trendsRate Hike & Smart Money Movement Tracker - baoquankhu1.vn
Biotech Genelux to stream CEO and team in live Titan Partners fireside chat - Stock Titan
Genelux Announces Underwritten Public Offering to Raise Capital - The Globe and Mail
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock | GNLX Stock News - Quiver Quantitative
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock - Yahoo Finance
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Nigeria
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Genelux data update indicates disease early control, says H.C. Wainwright - MSN
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com South Africa
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com Canada
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux Appoints Veteran Oncologist Jason Litten as CMO - The Globe and Mail
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Corporation Announces Change of Chief Medical Officer - marketscreener.com
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):